Cerebrospinal fluid plasminogen, plasmin and protease inhibitors in multiple sclerosis

Fibrinolysis and Proteolysis

Volumn 13, Issue 3, 1999, Pages 99-103

  Akenami, F O T ^a   Koskiniemi, M ^a   Farkkila M ^b   Vaheri, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMIN; PLASMINOGEN; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CELL MIGRATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPLEX FORMATION; DEMYELINATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; ZYMOGRAPHY;

EID: 0032770499     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(99)90095-4     Document Type: Article

References (47)

1. Hauser S L. Multiple sclerosis and other demyelinating diseases. In: Isselbacher K et al. (eds) Harrison's principles of internal medicine, 13th ed. New York: McGraw-Hill, 1994; 2287-2295.
2. Hauser SL, Aubert C, Burks JS et al. Analysis of human T lymphotropic virus sequences in multiple sclerosis tissue. Nature 1986; 322: 176-177.
3. Gijbels KS, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
4. Akenami FOT, Sirén V, Koskiniemi M, Siimes MA, Teräväinen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996; 49: 577-580.
5. Akenami FOT, Koskiniemi M, Mustjoki S, Siren V, Färkkilä M, Vaheri A. Plasma and cerebrospinal fluid activities of tissue plasminogen activator and urokinase in multiple sclerosis. Fibrinolysis & Proteolysis 1997; 11: 109-113.
6. Akenami FOT, Koskiniemi M, Färkkilä M, Vaheri A. Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological diseases. J Clin Pathol 1997; 50: 157-160.
7. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen K, Nielsen L, Skriver L. Plasminogen activators, Tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-166.
8. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-328.
9. Carroll PM, Tsirka SE, Richards WG, Frohman MA, Strickland S. The mouse tissue plasminogen activator gene 5′ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 1994; 120: 3173-3183.
10. Garcia-Rocha M, Avila J, Armas-Porte R. Tissue-type plasminogen activator (tPA) is the main plasminogen activator associated with isolated rat nerve growth cones. Neurosci Lett 1994; 180: 123-126.
11. Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994; 81: 41-49.
12. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270: 1992-1994.
13. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384: 123-124.
14. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17: 543-552.
15. Palolahti M, Lauharanta J, Stephens RW, Kuusela P, Vaheri A. Proteolytic activity in leg ulcer exudate. Exp dermatol 1993; 2: 29-37.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-682.
17. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Ann Rev Immunol 1992; 10: 153-187.
18. Jiang H, Zhang S-I, Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 1992; 256: 1213-1215.
19. Koh D-R, Fung-Leung W-P, Ho A, Gray D, Acha-Orbea H, Mak T-W. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8 -/- mice. Science 1992; 256: 1210-1213.
20. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunology Today 1994; 15: 103-107.
21. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N. Involvement of cytokines in N-methyl-N′-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol 1993; 33: 358-362.
22. Norton WT, Brosnan CF, Cammer W, Goldmuntz EA. Mechanisms and suppression of inflammatory demyelination. Acta Neurobiol Exp Warsz 1990; 50: 225-235.
23. Dore-Duffy P, Donovan C, Todd RF 3rd. Expression of monocyte activation antigen Mo3 on the surface of peripheral blood monocytes from patients with multiple sclerosis. Neurology 1992; 42: 1609-1614.
24. Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 1993; 331: 243-248.
25. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. The expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 35: 89-97
26. Romanic AM, Madri JA. The extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994; 4: 145-156.
27. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-925.
28. Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science 1980; 208: 1036-1037
29. Kun-yu K, Jakobsen CD, Hoak JC. Plasminogen in normal and abnormal human cerebrospinal fluid. Arch Neurol 1973; 28: 64-66.
30. Nakajima K, Tauzaki N, Nagata K, Takemoto N, Kohsaka S. Production and secretion of plasminogen in cultured rat cell microglia. FEBS lett 1992; 308: 179-182.
31. Nakajima K, Nagata K, Hamanoue M, Takemoto N, Kohsaka S. Microglia-derived elastase produces a low-molecular-weight plasminogen that enhances neurite outgrowth in rat neocortical expiant cultures. J Neurochem 1993; 61: 2155-2163.
32. Sappino A, Madani R, Huarte J, Belin D, Kiss J, Wohlwend A, Vassalli JD. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92: 679-685.
33. Whitelaw A, Mowinckel M-C, Abildgaard U. Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? Acta Paediatr 1995; 84: 933-936.
34. Cuzner ML, Gveric D, Strand C et al. The expression of tissue-type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropath Exp Neurol 1996; 55: 1194-1204.
35. Akenami FOT, Sirén V, Wessman M, Koskiniemi M and Vaheri A. Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. J Neurol Sci 1999; in press.
36. Krystosek A, Seeds NW. Plasminogen activator release at neuronal growth cone. Science 1981; 213: 1532-1534.
37. Vaheri A, Salonen E-M. Fibronectin and regulation of proteolysis in cancer and tissue destruction. Proc Finn Dent Soc 1988; 84: 13-18.
38. He C, Wilhelm S, Pentland A, Marmer B, Grant G, Eisen A, Goldberg G. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-2636.
39. Setler-Stevenson W, Krutzsch H, Wacher M, Margulies I, Liotta L. The activation of human type IV collagenase proenzyme. JBiol Chem 1989; 264: 1353-1356.
40. Felgenhauer K, Schliep G, Rapic N. Evaluation of the hlood-CSF barrier by protein gradients and the humoral immune response within the central nervous system. J Neurol Sci 1978; 30: 113-128.
41. Fryden A, Link H, Norrby E. Cerebrospinal fluid and serum immunoglobulins and antibody titers in mumps meningitis and aseptic meningitis of other etiology. Infection & Immunity 1978; 21: 852-861.
42. Siemes H, Siegart M, Anefeld F. Febrile convulsions and hloodcerebrospinal fluid barrier. Epilepsia 1978; 19: 57-66.
43. Schliep G, Felgenhauer K. Rapid determination of proteins in serum and cerebrospinal fluid by laser-nephelometry. J Clin Chem & Clin Biochem 1978; 16: 631-635.
44. Felgenhauer K, Nekic M. Low molecular solutes and the blood cerebrospinal fluid barrier. Klinische Wochenschrift 1982; 60: 1385-1392.
45. Livrea P, Trojano M, Simone M, Zimnatore GB, Pisicchio L, Logroscino G, Cibelli G. Heterogeneous models for blood cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. J Neurol Sci 1984; 64: 245-258.
46. Price P, Cuzner ML. Proteinase inhibitors in cerebrospinal fluid in multiple sclerosis. J Neurol Sci 1979; 42: 251-259.
47. Rao NR, Pattabiraman TN. Alpha-2-macroglobulin, albumin and chymotrypsin inhibitory capacity in cerebrospinal fluid as indices of blood-cerebrospinal fluid barrier. Biochem Med & Metab Biol 1986; 36: 317-321.